SCHEMBL191733

SCHEMBL191733

Cc1nc2c[n+]([O-])c3cccnc3c2n1CC(C)C

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 3/20 0.31
APAF1 O14727 1/20 0.31
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
KDM4E B2RXH2 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL192091 0.86 TSHR (0.38) HTR2AHTR2CHTR2BTSHR
SCHEMBL14000523 0.86 ALDH1A1 (0.33) HTR2AHTR2CHTR2BSMN1; SMN2LMNA
SCHEMBL5124109 0.85 TP53 (0.32) HTR2AHTR2CHTR2BLMNA
SCHEMBL4061438 0.83 ALDH1A1 (0.36) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL4061433 0.83 ALDH1A1 (0.36) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL10734696 0.81 ALDH1A1 (0.40) SMN1; SMN2LMNATSHRHTTALDH1A1
SCHEMBL843383 0.80 ALDH1A1 (0.32) SMN1; SMN2LMNAHTTALDH1A1
SCHEMBL4056836 0.78 TLR7 (0.40) HTR2AHTR2CHTR2BSMN1; SMN2LMNA
SCHEMBL191697 0.76 LMNA (0.39) HTR2AHTR2CHTR2BSMN1; SMN2LMNA
SCHEMBL1456954 0.71 NPC1 (0.35) SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436176-B2 Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine MEDICIS PHARMACEUTICAL CORPORATION (US) 2013-05-07 US claimed
EP-1833827-B9 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE MEDA AB (SE) 2012-01-04 EP claimed
EP-1833827-B1 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE MEDA AB (SE) 2011-05-25 EP claimed
US-20080306266-A1 Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine 3M INNOVATIVE PROPERTIES COMPANY 2008-12-11 US claimed
EP-1833827-A2 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZOÝ4,5-C¨Ý1,5¨NAPHTHYRIDIN-4-AMINE 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-09-19 EP claimed
WO-2006074046-A2 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-07-13 WO claimed
US-8436176-B2 Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine MEDICIS PHARMACEUTICAL CORPORATION (US) 2013-05-07 US disclosed
EP-1833827-B9 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE MEDA AB (SE) 2012-01-04 EP disclosed
EP-1833827-B1 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE MEDA AB (SE) 2011-05-25 EP disclosed
US-20090240055-A1 Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof KREPSKI LARRY R 2009-09-24 US disclosed
US-20080306266-A1 Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine 3M INNOVATIVE PROPERTIES COMPANY 2008-12-11 US disclosed
EP-1937683-A1 METHOD FOR 1H-IMIDAZOÝ4,5-c¨PYRIDINES AND ANALOGS THEREOF Coley Pharmaceutical Group, Inc. (US) 2008-07-02 EP disclosed
EP-1833827-A2 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZOÝ4,5-C¨Ý1,5¨NAPHTHYRIDIN-4-AMINE 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-09-19 EP disclosed
WO-2007035935-A1 METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-03-29 WO disclosed
WO-2006074046-A2 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240055-A1 Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof CYP4B1, CYP4F8, CYP4X1 HTR2A 3613/4885HTR2C 1979/4885HTR2B 2513/4885
US-20080306266-A1 Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine DNMT1, NT5C, JMJD1C HTR2A 322/4885HTR2C 51/4885HTR2B 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.